CO5690536A2 - Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad - Google Patents

Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad

Info

Publication number
CO5690536A2
CO5690536A2 CO06045059A CO06045059A CO5690536A2 CO 5690536 A2 CO5690536 A2 CO 5690536A2 CO 06045059 A CO06045059 A CO 06045059A CO 06045059 A CO06045059 A CO 06045059A CO 5690536 A2 CO5690536 A2 CO 5690536A2
Authority
CO
Colombia
Prior art keywords
solids
amorph
dispersions
mtp inhibitor
obesity treatment
Prior art date
Application number
CO06045059A
Other languages
English (en)
Spanish (es)
Inventor
Dwayne Thomas Friesen
Ravi Mysore Shanker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5690536A2 publication Critical patent/CO5690536A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CO06045059A 2003-11-14 2006-05-12 Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad CO5690536A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51993103P 2003-11-14 2003-11-14

Publications (1)

Publication Number Publication Date
CO5690536A2 true CO5690536A2 (es) 2006-10-31

Family

ID=34590458

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06045059A CO5690536A2 (es) 2003-11-14 2006-05-12 Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad

Country Status (16)

Country Link
US (1) US20080293801A1 (enExample)
EP (1) EP1696887A1 (enExample)
JP (1) JP2007511500A (enExample)
KR (1) KR20060096076A (enExample)
CN (1) CN1878538A (enExample)
AR (1) AR048206A1 (enExample)
AU (1) AU2004289110A1 (enExample)
BR (1) BRPI0416596A (enExample)
CA (1) CA2545443A1 (enExample)
CO (1) CO5690536A2 (enExample)
IL (1) IL175372A0 (enExample)
MX (1) MXPA06005489A (enExample)
NO (1) NO20062778L (enExample)
NZ (1) NZ546677A (enExample)
TW (1) TW200515909A (enExample)
WO (1) WO2005046644A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0619989A2 (pt) * 2005-12-15 2011-10-25 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, métodos para o tratamento e/ou prevenção de enfermidades que estão associados com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
JP5711151B2 (ja) * 2010-01-06 2015-04-30 武田薬品工業株式会社 インドール誘導体
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4884235A (en) * 1988-07-19 1989-11-28 Thiele Alfred A Micromagnetic memory package
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
RS50712B (sr) * 2001-06-28 2010-06-30 Pfizer Products Inc. Triamid-supstituisani indoli, benzofurani i benzotiofeni kao inhibitori mikrozomalnog triglicerid transfer proteina (mtp) i/ili sekrecije apolipoproteina b (apo b)
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Also Published As

Publication number Publication date
NZ546677A (en) 2008-11-28
BRPI0416596A (pt) 2007-01-30
US20080293801A1 (en) 2008-11-27
MXPA06005489A (es) 2006-08-11
EP1696887A1 (en) 2006-09-06
CA2545443A1 (en) 2005-05-26
AR048206A1 (es) 2006-04-12
NO20062778L (no) 2006-08-14
KR20060096076A (ko) 2006-09-05
JP2007511500A (ja) 2007-05-10
IL175372A0 (en) 2006-09-05
AU2004289110A1 (en) 2005-05-26
WO2005046644A1 (en) 2005-05-26
CN1878538A (zh) 2006-12-13
TW200515909A (en) 2005-05-16

Similar Documents

Publication Publication Date Title
BRPI0501449A (pt) Mistura funcional, processos para curar e para curar parcialmente uma mistura funcional, e, adesivo
GB2457416A (en) Directly photodefinable polymer compositions and methods thereof
GT200600283A (es) COMPUESTOS DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA LA MODULACIÓN DE LA beta-SECRETASA
CR10127A (es) Agente para la prevención o tratamiento de neuropatías (divisional exp. 7849)
DE602006019788D1 (de) Oximester-Fotoinitiatoren
TW200510509A (en) Dendrimer compound and organic luminescent device using the same
TW200619186A (en) New compound and organic light-emitting device using the same (9)
BRPI0710266B8 (pt) composto, medicamento, e, uso de um composto
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
EP2949644A3 (en) Substituted tetracycline compounds
AR039701A1 (es) Combinaciones de compuestos activos fungicidas
ATE386043T1 (de) Metallocene und von ihnen abgeleitete katalysatorzusammensetzungen
NO20074005L (no) Antisugvaeske til bruk i underjordiske formasjoner
CR20130666A (es) Composición de emulsión estable (divisional expediente 9495)
BR0113986B1 (pt) mÉtodo para inibir o crescimento de microorganismos em um lÁtex, e, composiÇço.
AR043783A1 (es) Difenilazetidinona con propiedades fisiologicas, medicamentos que comprenden este compuesto y su uso
CY1115247T1 (el) Ενωσεις συμπυκνωμενων δακτυλιων και χρηση αυτων
IS7482A (is) Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyf
DE502006004808D1 (de) O/w wachsdispersionen und hieraus erhältliche gipsprodukte
CO5690536A2 (es) Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad
AR060107A1 (es) Inhibidor de polimerizacion para la estabilizacion de monomeros insaturados olefinicamente
AR025296A1 (es) MÉTODO PARA INHIBIR LA POLIMERIZACIoN PREMATURA DE MONoMEROS VINIL AROMÁTICOS Y COMPOSICIoN DE MONoMEROS VINIL AROMÁTICOS Y DEL INHIBIDOR.
BR0312608A (pt) Adjuvantes lìquidos
CO5690608A2 (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica
CO5400148A1 (es) Derivados de pirazoles que son antagonistas de cck-1